# V1 Empirics Check — openai/gpt-oss-120b (Variant B)

**Model:** openai/gpt-oss-120b
**Variant:** B
**Date:** 2026-03-25T16:05:04.137271

---

**Review of “The Transposition Mirage: Why EU Telecom Reform Appears to Cut Prices but Doesn’t”**  
*AER: Insights*  

---

### 1. Idea Fidelity  

The manuscript follows the original manifest closely in most respects:  

* **Policy and timing** – It uses the staggered transposition dates of the EU Electronic Communications Code (EECC) (2020‑2025) exactly as described.  
* **Data source** – The primary outcome is the Eurostat HICP communications index (COICOP CP08), and the same placebo series (food, transport, housing) are employed, matching the manifest.  
* **Identification strategy** – The authors adopt the Callaway‑Sant’Anna (2021) staggered DiD estimator (CS‑DiD) and compare results with a conventional two‑way fixed‑effects (TWFE) regression, as prescribed.  
* **Research question** – The paper asks whether the EECC reduced consumer telecom prices and, more broadly, whether the timing of transposition can be treated as exogenous.  

The only notable departure from the manifest is the **conclusion**: the original idea anticipated a positive welfare‑relevant effect of the EECC (and a quantification of the cost of regulatory delay). The authors instead find that parallel‑trend assumptions are violated and that the treatment effect is statistically indistinguishable from zero. This shift is acceptable—discovering that the natural‑experiment design fails is itself a contribution—but it requires a more explicit discussion of why the original identification strategy broke down and what alternative strategies might salvage causal inference.  

Overall, the paper stays true to the manifest’s data, timing, and methodological framework; it merely diverges in its empirical outcome.

---

### 2. Summary  

The article evaluates the consumer‑price impact of the EU Electronic Communications Code by exploiting the staggered national transposition dates across 27 EU members (plus Norway and Switzerland). Using a CS‑DiD estimator, the authors find a negligible overall effect (‑0.9 index points) and, crucially, robust violations of the parallel‑trend assumption and significant placebo effects, suggesting that transposition timing is endogenous to pre‑existing price dynamics. The paper therefore delivers a methodological caution: EU directive‑transposition timing may not provide a credible source of quasi‑experimental variation when the policy targets the very conditions that drive compliance speed.

---

### 3. Essential Points  

| # | Issue | Why it matters | What the authors must do |
|---|-------|----------------|--------------------------|
| **1** | **Failure of the parallel‑trends assumption** – The event‑study shows large, significant negative leads (‑2 to ‑8 index points) for the treated group, and placebo outcomes also exhibit sizable “effects.” | Without parallel trends, the CS‑DiD estimates are not causal; the entire identification strategy collapses. | Provide a **credible alternative identification** (e.g., (i) use *not‑yet‑treated* countries as dynamic controls, (ii) implement a synthetic‑control or matched‑pair design for each cohort, (iii) exploit exogenous “implementation lag” variables such as the date of first enforcement actions rather than the notification date). Demonstrate that at least one of these approaches restores parallel trends or, if not possible, acknowledge that a causal estimate cannot be obtained with the available data. |
| **2** | **Mis‑classification of never‑treated units** – Italy, Lithuania, Poland, and Slovakia are treated later in the sample and are therefore *not* true never‑treated units; they belong to the staggered adoption and have systematically higher price growth. | Using them as a control group biases the ATT upward or downward and makes placebo tests unreliable. | Re‑define the control group to consist only of **non‑EU** countries (e.g., Norway, Switzerland, Iceland) or, better, construct **cohort‑specific never‑treated groups** that exclude any country that will eventually receive the treatment. Re‑run the main CS‑DiD with this revised comparator and report how the ATT changes. |
| **3** | **Outcome aggregation masks heterogeneous channels** – The HICP communications index bundles mobile voice, broadband, postal services, and equipment, potentially diluting any effect that is limited to a sub‑sector (e.g., broadband prices). | A null effect on the aggregate index does not rule out important sector‑specific effects, which are policy‑relevant. | Disaggregate the CPI into its component series (e.g., separate indices for mobile voice, fixed broadband, and postal services) and repeat the analysis. If component‑level data are unavailable, complement the CPI with **micro‑price data** from national regulators or commercial datasets (e.g., monthly mobile termination rates, broadband subscription fees). This will sharpen the substantive conclusion and improve the paper’s contribution. |

If any of these three points cannot be adequately addressed, the paper should be **rejected** on the grounds that it does not deliver a credible causal estimate.

---

### 4. Suggestions  

Below are a set of constructive recommendations—most of which are optional but would considerably strengthen the manuscript, improve its credibility, and increase its relevance for both policy‑evaluation and methodological audiences.

#### A. Strengthen the Identification Narrative  

1. **Explicitly diagnose the source of endogeneity** – The paper hints that countries with “already‑declining prices” transposed early, but a more rigorous discussion (e.g., linking pre‑treatment price trends to political variables such as coalition composition, legislative capacity, or prior regulatory intensity) would clarify the mechanism.  
2. **Instrumental‑variable (IV) approach** – If an exogenous driver of transposition timing exists (e.g., the timing of EU infringement‑procedure initiation dates, or the date of the European Commission’s “implementation guidance” release), it could serve as an IV for the actual transposition date. Even a weak‑instrument test would be informative.  
3. **Dynamic treatment effects** – The current event study stops at two years post‑treatment. Extending the horizon to 4–5 years could capture delayed enforcement effects, especially given that NRAs often need time to implement wholesale‑access obligations.  

#### B. Refine the Control Group  

1. **Pure never‑treated set** – As noted, Italian, Lithuanian, Polish, and Slovakian cases are not “never‑treated.” Use a set of **external European countries** that are not subject to the EECC (e.g., Norway, Switzerland, Iceland, the United Kingdom if data are available) as the baseline.  
2. **Balanced panel** – Ensure the control group has the same pre‑treatment observation window as the treated groups to avoid bias from differing lengths of histories.  
3. **Weighting** – Apply **entropy‑balancing or propensity‑score weighting** to align pre‑treatment covariates (GDP per capita, telecom penetration, market concentration) across treated and control units. This can alleviate concerns that the never‑treated differ systematically from treated countries.  

#### C. Data Enhancements  

1. **Higher‑frequency data** – Monthly HICP series are available for many CPI components. Switching to a **quarterly or monthly** frequency would increase the number of pre‑treatment periods, improve power, and allow a finer test of anticipation effects.  
2. **Disaggregate the CPI** – Eurostat publishes separate HICP sub‑indices for “mobile telephone services,” “fixed broadband services,” and “postage services.” Estimating the effect on each component could reveal that, for example, **mobile voice prices** fell while **broadband prices** rose, yielding a net zero effect on the aggregate.  
3. **Regulatory enforcement dates** – The paper treats the **notification date** as the treatment date, but the economic impact likely follows the **first enforcement action** (e.g., the issuance of wholesale‑access fees). Collecting these dates from national regulatory authorities (BEREC national reports) would provide a more accurate timing variable.  

#### D. Robust Inference  

1. **Few‑cluster adjustments** – With only ~30 country clusters, conventional cluster‑robust SEs can be unreliable. Employ **wild cluster bootstrap** (e.g., Cameron, Gelbach, and Miller 2008) or **t‑distribution with degrees of freedom equal to the number of clusters**. Report both standard errors.  
2. **Placebo permutations** – Besides the three CPI categories used, randomly assign treatment dates to control units many times (e.g., 1,000 permutations) to construct an empirical null distribution. This “falsification test” would strengthen the claim that the observed placebo effects are not artifacts of the estimator.  

#### E. Presentation and Transparency  

1. **Code and reproducibility** – The manuscript notes an autonomous generation pipeline. Provide a **GitHub repository** with scripts for data cleaning, treatment‑date construction, and estimation (including all robustness checks). A README that guides the reviewer through replication would be highly appreciated.  
2. **Figures** – Replace the tabular event‑study with a **graphical event‑study plot** (coefficients with 95 % confidence bands). Visual inspection aids the reader in assessing the magnitude of pre‑trend violations.  
3. **Policy relevance** – Expand the discussion on the welfare implications of *regulatory delay*. Even if the EECC had no measurable price impact, the paper could estimate the *counterfactual cost* of a “one‑year delay” using the observed pre‑trend differentials, thereby preserving the original motivation of quantifying the cost of delay.  

#### F. Theoretical Framing  

1. **Link to “policy endogeneity” literature** – Cite recent work on the “policy endogeneity problem” in staggered designs (e.g., Borusyak, Jaravel, and Spiess 2024; Sun and Abraham 2021). Position the paper as an empirical illustration of this problem in the EU regulatory context.  
2. **Potential mechanisms** – Discuss why the EECC might plausibly affect prices (e.g., reduced switching costs, wholesale‑access constraints) and why those mechanisms could be muted (e.g., pre‑existing competition, vertical integration). A brief structural model or a set of testable predictions helps readers evaluate the plausibility of a null effect.  

#### G. Minor Technical Points  

* **Treatment coding** – Clarify whether the “year of transposition” is coded as 1 for the *full calendar year* or for *the exact month*; if the latter, consider using a **fractional treatment variable** to avoid measurement error.  
* **Standardized effect sizes** – Table A.1 reports a “large negative” SDE for the aggregate CPI despite the point estimate being statistically insignificant. Consider renaming the classification to “non‑significant” to avoid over‑stating the magnitude.  
* **Appendix** – Include a full list of transposition dates, source URLs, and any cases where the official date differs from the journal’s 2020/2021/2022 categorisation.  

---

### Concluding Remarks  

The manuscript makes a valuable contribution by highlighting the pitfalls of using EU directive transposition timing as a quasi‑experimental source. However, the core causal claim is undermined by clear violations of the parallel‑trend assumption and by an ambiguous control‑group definition. Addressing the three essential points—restoring credible identification, redefining the never‑treated set, and examining sector‑specific outcomes—will be necessary for the paper to meet AER: Insights standards.  

If the authors can either (i) demonstrate that a revised identification strategy yields a credible ATT, or (ii) convincingly argue that the data *cannot* support a causal estimate and re‑frame the contribution as a methodological caution, the paper will be a solid addition to the literature on EU policy evaluation. The extensive set of suggestions above should help the authors achieve that goal.
